MDGL vs MYGN: fair value comparison
Madrigal Pharmaceuticals, Inc. and Myriad Genetics, Inc. · Updated 2026-10-19
MDGL's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. MYGN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MDGL currently ranks higher by quality score.
| MDGL | MYGN | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $449.74 | $3.98 |
| 12-month range | $412.35–$602.83 | $2.86–$8.18 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #200 of 301 Healthcare | #201 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: MDGL fair value analysis · MYGN fair value analysis